Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment
VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.